Immunoglobulin A Nephropathy – Unmet Need – Unmet Need – IgA Nephropathy (US/EU)
IgA nephropathy, also known as Berger’s disease, is a rare autoimmune disease affecting the kidneys. It is characterized by predominant IgA protein deposition and impairment of blood filtration in the kidneys’ tiny blood channels. The IgAN drug market comprises supportive treatments such as antihypertensive drugs, immunosuppressants, and diuretics. The only approved therapy for IgAN is Tarpeyo (a delayed-release budesonide capsule). A high unmet need exists for effective treatments that can meaningfully delay or halt this progressive end-stage kidney disease. In this report, we analyze the attributes that drive nephrologists to prescribe a therapy. The conjoint analysis establishes physicians’ preferences for prescribing emerging drugs and assesses if these emerging therapies can capitalize on these unmet needs.
Questions answered
- How do nephrologists rate the performance of current IgAN treatments, such as RAAS inhibitors, SGLT-2 inhibitors, and corticosteroids, against treatment drivers and goals?
- What drug attributes are key influencers, which have limited impact, and which are hidden opportunities?
- What trade-offs across different clinical attributes and price are acceptable to U.S. and European physicians for new IgAN drugs to be preferred over current treatment options?
- What are the major areas of opportunity for drug developers in IgAN treatment and their likelihood of being fulfilled in the near future?
Product description
Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by Clarivate experts, and additional customized market scenarios can be evaluated with the corresponding TPP Simulator.
Key feature
The Target Product Profile (TPP) Simulator tool allows for customizable market simulations based on conjoint analysis that depicts how physicians make decisions based on actual behavior rather than opinion. Compare up to seven TPPs across multiple disease-specific attributes and price points to gauge which variables influence prescribing behavior.
Markets covered: United States, France, Germany, United Kingdom
Primary research: 62 U.S. and 33 European nephrologists surveyed in February 2024
Key companies: Calliditas Therapeutics, Travere Therapeutics, Eli Lilly / Boehringer Ingelheim, Johnson & Johnson
Key drugs: RAAS inhibitors, diuretics, Tarpeyo / Kinpeygo, corticosteroids, other immunosuppressants, SGLT-2 inhibitors, Filspari
